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ABSTRACT
The recent finding that MYC-driven cancers are sensitive to inhibition of the 
DNA damage response (DDR) pathway, prompted us to investigate the role of DDR 
pathway as therapeutic target in diffuse large B-cell lymphoma (DLBCL), which 
frequently overexpresses the MYC oncogene. In a preliminary immunohistochemical 
study conducted on 99 consecutive DLBCL patients, we found that about half of 
DLBCLs showed constitutive expression of the phosphorylated forms of checkpoint 
kinases (CHK) and CDC25c, markers of DDR activation, and of phosphorylated histone 
H2AX (γH2AX), marker of DNA damage and genomic instability. Constitutive γH2AX 
expression correlated with c-MYC levels and DDR activation, and defined a subset of 
tumors characterised by poor outcome. Next, we used the CHK inhibitor PF-0477736 
as a tool to investigate whether the inhibition of the DDR pathway might represent a 
novel therapeutic approach in DLBCL. Submicromolar concentrations of PF-0477736 
hindered proliferation in DLBCL cell lines with activated DDR pathway. These results 
were fully recapitulated with a different CHK inhibitor (AZD-7762). Inhibition of 
checkpoint kinases induced rapid DNA damage accumulation and apoptosis in DLBCL 
cell lines and primary cells. These data suggest that pharmacologic inhibition of 
DDR through targeting of CHK kinases may represent a novel therapeutic strategy 
in DLBCL.
INTRODUCTION
Diffuse large B cell lymphoma (DLBCL), 
the most common non Hodgkin lymphoma (NHL) 
subtype, is characterized by an aggressive clinical 
course [1], and standard first line R-CHOP (Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) 
chemoimmunotherapy results in approximately 60% cure 
rates [2].
In the last ten years gene expression profiling has 
identified two distinct signatures strongly related to the 
outcome and response to therapy, the germinal center (GCB) 
B-cell and the activated B-cell (ABC) signatures [3–5], 
but this classification did not translate yet in a tailored 
therapeutic approach, as the International prognostic 
index (IPI) risk score (based on clinical variables), 
remains the most reliable prognostic tool available in 
clinical practice [2]. Interestingly, recent data show that 
a significant fraction of DLBCL display chromosomal 
segregation defects and aneuploidy, a prominent feature 
of instable genomes, and these characteristics have 
been demonstrated to correlate with poor prognosis 
following conventional R-CHOP chemoimmunotherapy 
[6]. Accordingly, whole exome sequencing studies showed 
that DLBCLs are characterized by a particularly large 
number of genomic aberrations [7]. Moreover a consistent 
percentage of DLBCLs are characterized by increased 
c-MYC expression [8–10] which is linked mechanistically 
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to instrinsic genomic instability by a mechanism called 
replicative stress, consisting in DNA damage accumulation 
during the S phase of the cell cycle [11].
Genomic instability is now considered a hallmark of 
cancer, which indicates a tendency toward accumulation 
of DNA damage with progressive acquisition of 
mutations and genomic abnormalities, favouring cancer 
development, metastatic phenotypes and chemoresistance 
[11, 12]. Following DNA damage, cells normally respond 
by activating the DNA damage repair pathway (DDR), 
which results in cell cycle arrest, DNA repair or eventually 
p53-mediated cell death [13]. The ataxia telangiectasia 
mutated (ATM) and ataxia telangiectasia and RAD3-
related protein (ATR) kinases are activated following 
DNA double and/or single strand breaks and in turn 
they phosphorylate the downstream targets checkpoint 
kinases (CHK) 1 and 2, and the histone H2AX, which 
is considered to be a reliable DNA damage marker [13–
15]. CHK1 and CHK2 activation triggers the inhibitory 
phosphorylation of the CDC25 phosphatases, which 
results in delayed mitotic entry, ensuring appropriate DNA 
repair at the G2/M checkpoint [13].
Accordingly it has been recently demonstrated 
that tumours bearing high levels of oncogene-induced 
replicative stress, such as MYC driven aggressive 
lymphoma mouse models and neuroblastoma, are sensitive 
to single agent CHK inhibitors [16–18].
On the other hand recent studies show that a subset 
of DLBCLs display mutations of genes involved in DNA 
repair [19]. Although the functional consequences of 
specific mutations have not been elucidated yet, these 
data further highlight the role of the DDR pathway 
in DLBCL pathogenesis. Therefore, inhibition of the 
DNA damage repair pathway may represent a valid 
therapeutic approach to fight cancers with aberrant DDR 
activation and CHK inhibitors are currently being tested 
in clinical trials in combination with DNA damaging 
agents (chemotherapy and radiotherapy) in a variety of 
tumors [20,21]. Taken together these findings represent a 
strong rationale to investigate the functional role of the 
DDR pathway in DLBCL, and to ascertain whether its 
components might represent potential therapeutic targets. 
Here we demonstrated that 1) a substantial fraction of 
DLBCLs display constitutive expression of the DNA 
damage marker γH2AX, which was associated with 
poor prognosis following conventional R-CHOP/CHOP-
like chemoimmunotherapy, 2) that c-MYC expression, 
γH2AX and DDR activation were significantly associated, 
confirming the intimate relationship between oncogene–
induced genomic instability and DDR activation in 
DLBCL, and 3) that DLBCL cell lines and primary cells 
exhibiting constitutive activation of the DDR pathway 
are very sensitive to the inhibition of checkpoint kinases. 
Taken together these data suggest that pharmacologic 
inhibition of DDR through targeting of CHK kinases may 
represent a new promising therapeutic strategy in the 
subset of DLBCLs with activated DDR pathway.
RESULTS
Constitutive activation of DDR components 
and genomic instability in diffuse large B-cell 
lymphomas
We assessed by immunohistochemistry the 
expression levels of the components of the DDR pathway 
(CHK1, CHK2, CDC25c) and their phosphorylated 
forms in three reactive lymphnodes, 27 cases of small 
lymphocyte lymphoma (SLL), 18 marginal zone 
lymphoma (MZL), 44 Hodgkin lymphoma (HL), 22 
Burkitt lymphoma (BL), and 99 consecutive DLBCL cases 
diagnosed at our Institution from 2002 to 2011.
Components of the DDR pathway CHK1, CHK2 
and CDC25c resulted to be expressed in 100% of B cell 
neoplasms and normal reactive follicles tested (Table 1) but 
only aggressive lymphomas (BLs and DLBCLs) showed a 
significant activation of DDR pathway, as demonstrated 
by the expression of CHK1, phosphorylated at ser 345, 
and CDC25c, phosphorylated at ser 216 (Table 1). The 
phosphorylated form of the CHK2 kinase at thr 68 was 
found to be expressed only in a minority of DLBCL cases 
(5%) (Table 1).
We thus hypothesized that lymphomas with 
constitutive activation of the DDR pathway would be 
characterized by higher levels of inherent genomic 
instability. In order to verify this hypothesis we investigated 
the expression of the phosphorylated form of the histone 
H2AX at serine 139 (γH2AX), a marker of DDR activation 
and DNA double strand breaks [13–15], in our B-cell 
lymphoma panel. Remarkably DLBCLs showed the highest 
constitutive γH2AX expression with 47% of positive cases 
(defined as percentage of positive cells ≥ 30%, in the 
methods section), confirming that DLBCL is a neoplasm 
characterized by high genomic instability and inherent DNA 
damage (Figure 1A, 1B). Reactive follicles and indolent 
B-cell lymphomas (MZL and CLL) showed low or absent 
expression of activated DDR components and γH2AX, and 
Hodgkin lymphoma cases showed intermediate expression 
(18% of γH2AX positive cases) (Table 1, Figure 1A, 1B).
By using cluster analysis on immunohistochemical 
results, considering the whole panel of DDR activation 
markers, aggressive B-cell neoplasms (DLBCL and BL) 
clearly clustered together, being characterized by higher 
constitutive CHK1, CDC25c, and H2AX phosphorylation, 
whereas indolent B-cell neoplasms and HL formed a 
separate cluster (Figure 1A).
Since high inherent genomic instability favours 
cancer progression and chemoresistance we next 
investigated the prognostic significance of constitutive 
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γH2AX expression and DDR activation in DLBCL 
patients. All patients were diagnosed and treated with 
chemoimmunotherapy at our institution. Characteristics 
of patients and univariate analyses are shown in Table S1. 
The spectrum of γH2AX expression is shown in Figure 1C. 
In the univariate analysis, pCDC25c ser 216 and γH2AX 
overexpression were significantly associated with worse 
overall survival (Table S1), as well as age≥60 years, IPI 
score > 2 and bcl-2/MYC double positivity. Remarkably 
5-year OS was 41% for γH2AX positive vs 70% for 
γH2AX negative patients (Figure 1D). Interestingly, 
the prognostic significance of γH2AX was particularly 
evident in the low-intermediate risk IPI group (0–2 risk 
factors), identifying a subgroup characterized by worse 
outcome (55% 5-year OS) (Figure 1E). In the multivariate 
framework γH2AX was found to be an independent 
prognostic predictor (Table S2). These results suggest 
that constitutive γH2AX expression is an independent 
negative prognostic predictor in DLBCL, being able to 
identify patients with poor prognosis even within the low-
intermediate risk group according to the IPI score.
c-MYC, γH2AX and DDR activation markers 
are frequently co-expressed in DLBCL
Since it has been reported that MYC-driven 
replicative stress leads to inherent DNA damage [11, 
12, 17, 18], we evaluated the correlation between 
c-MYC, γH2AX (marker of DNA damage) and 
pCHK1/2 (pCHK1+pCHK2) and pCDC25c expression 
(markers of DDR activation), hypothesizing that γH2AX 
positive DLBCLs would be characterized by c-MYC 
overexpression and enhanced DDR activation.
The 99 patients considered in the survival analysis 
were divided in 2 groups based on γH2AX expression 
levels. By using Fisher’s exact test we found a statistically 
significant association between γH2AX positivity, c-MYC 
expression, and increased activation of CDC25c and CHK 
kinases (Figure 1F) (Table 2). Interestingly non-GCB and 
GCB cases, low and high risk IPI score patients were 
equally distributed in the γH2AX positive and negative 
groups (Table 2).
Also by categorizing patients in 2 groups depending 
on the c-MYC expression status, we could confirm the 
association between c-MYC, γH2AX, pCDC25c and 
pCHK1/2 kinases expression: of note γH2AX positive 
cases raised from 37% to 63%, pCHK1/2 positive 
cases from 28% to 55%, pCDC25c positive cases from 
24% to 55% from the c-MYC negative to the c-MYC 
positive group (Figure 1G). These results indicate a tight 
association between c-MYC expression, inherent genomic 
instability, and constitutive DDR activation.
Inhibition of checkpoint kinases hinders 
proliferation and promotes apoptotic death in 
DLBCL cells
The observation that about half of the DLBCL cases 
were characterised by constitutive γH2AX expression, 
which was associated with adverse outcome and with 
activation of the DDR pathway, suggests that inhibition 
of the DDR may represent a promising new therapeutic 
strategy to fight this subset of tumours.
Therefore, we explored the effect of DDR pathway 
inhibition in a series of human B-cell NHL cell lines, 
including 6 DLBCL cell lines, 1 BL and 1 HL cell line 
(used respectively as a positive and negative control for 
constitutive DDR activation). All the DLBCL cell lines, 
irrespectively of their GC or ABC origin, and the BL cell 
line RAMOS showed some activation of the DDR pathway, 
as defined by constitutive phosphorylation of CHK1 
at ser 345 and/or phosphorylation of CHK2 at thr 68, 
Table 1. Immunohistochemical results
Tumor type CHK1 pCHK1 CHK2 pCHK2 CDC25 pCDC25 γH2AX
pos (%) pos (%) pos (%) pos (%) pos (%) pos (%) pos (%)
RL 3/3 (100) 0/3 (0) 3/3 (100) 0/3 (0) 3/3 (100) 0/3 (0) 0/3 (0)
CLL/SLL 27/27 (100) 2/27 (7) 27/27 (100) 0/27 (0) 27/27 (100) 0/27 (0) 3/27 (11)
SMZL 18/18 (100) 2/18 (11) 18/18 (100) 0/18 (0) 18/18 (100) 0/18 (0) 1/18 (5)
CHL 44/44 (100) 6/44 (14) 44/44 (100) 3/44 (7) 44/44 (100) 9/44 (20) 8/44 (18)
BL 22/22 (100) 10/22 (45) 22/22 (100) 3/22 (14) 22/22 (100) 18/22 (82) 5/22 (23)
DLBCL 99/99 (100) 38/99 (38) 99/99 (100) 5/99 (5) 99/99 (100) 40/99 (40) 47/99 (47)
Abbreviations: positive (pos), negative (neg), reactive lymph nodes (RL), chronic lymphocytic leukaemia/small lymphocyte 
lymphoma (SLL), marginal zone lymphomas (MZL), classical Hodgkin lymphoma (CHL), Burkitt lymphoma (BL), diffuse 
large B –cell lymphomas (DLBCL).
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Figure 1: The DDR pathway is aberrantly active in DLBCL. (A) Hierarchical clustering, displayed in a dendrogram, showing 
higher constitutive activation of the DDR pathway and γH2AX staining in aggressive non Hodgkin B-cell lymphomas (DLBCL and BL), 
compared to indolent B-cell lymphoma subtypes (CLL, SMZL), HL and reactive follicles (RF) . The level of expression in each lymphoma 
type and in RF, that is the number of positive cases/number of evaluable cases, is represented by a color scale, starting from grey, indicating 0% 
of the samples positive, up to brilliant red, indicating 85% of the samples positive (the maximum percentage of positivity detected was 82%). 
The highest levels of γH2AX and pCHK1ser 345 staining were observed in DLBCL, with 47% and 38% of cases expressing respectively 
γH2AX and pCHK1 ser 345 in more than 30% of cells. (B) Representative TMA spots of reactive follicles (RF) (a-d), CLL (e-h), SMZL 
(i-l) HL (m-p), BL (q-t) and DLBCL (u-x) stained for pCHK1, pCHK2, pCDC25c and γH2AX. Higher expression levels of activated DDR 
pathway components and γH2AX were observed in DLBCL and BL, compared to indolent NHL subtypes and HL, showing low or absent 
DDR activation and γH2AX staining. (C) Table showing the spectrum of γH2AX expression in our DLBCL cohort. (D) Overall survival 
(OS) curve of γH2AX positive compared to γH2AX negative DLBCL patients. 99 consecutive DLBCL patients diagnosed and treated at our 
institution with Rituximab plus CHOP/CHOP-like regimens from 2002 to 2011 were considered. Patients positive (pos) for γH2AX at initial 
diagnosis had a significant inferior OS rates compared to γH2AX negative (neg) ones (with 5-year OS rate of 41% vs 70% respectively, p < 
0.01, log-rank test). (E) Overall survival curve of the low-intermediate risk IPI group according to the γH2AX status. 63 patients with low-
intermediate risk IPI score (0–2) were considered in this subgroup analysis. The 5-year OS of γH2AX positive patients resulted significantly 
lower compared to the OS of γH2AX negative patients, with 5-year OS rate of 55% vs 83% respectively (p < 0.01, log-rank test).
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Table 2. Characteristics of γH2AX negative and positive DLBCL patients with respect to IPI score, 
p53 expression levels, cell of origin (GCB vs non-GCB), Bcl-2 expression, c-MYC expression, and 
DDR pathway activation (pCHK1/2, pCDC25c)
Factor γH2AX- (N=52) γH2AX+ (N=47) Missing p-value (Fisher’s 
exact test)
IPI 0 0.67
Low (0–2) 34 (65%) 29 (62%)
High (3–4) 18 (35%) 18 (38%)
p53 2 (2%) 0.16
< 50% 42 (81%) 32 (68%)
≥ 50% 9 (17%) 14 (30%)
Ki-67 0 0.82
< 90% 35 (67%) 31 (66%)
≥ 90% 17 (33%) 16 (34%)
Cell of Origin 0 0.45
GCB 26 (50%) 20 (43%)
Non-GCB 26 (50%) 27 (57%)
Bcl-2 0 0.89
< 70% 15 (29%) 13 (28%)
≥ 70% 37 (71%) 34 (72%)
c-MYC 3 (3%) 0.01
< 40% 31 (60%) 18 (38%)
≥ 40% 18 (35%) 29 (62%)
Figure 1: (Continued) (F) Bar graphs showing a significantly increased incidence of c-MYC, pCDC25c, and pCHK1/2 positive cases in the 
γH2AX positive subgroup, compared to the γH2AX negative subgroup. The incidence of c-MYC positive cases raised from 35% to 62%, 
from the γH2AX negative to γH2AX positive group (p = 0.02) (Fisher’s exact test). *P < 0.05; **P < 0.005. The incidence of pCDC25c 
positive cases increased from 17% to 66% from the γH2AX negative to the γH2AX positive group (p < 0.001) (Fisher’s exact test).The 
incidence of pCHK1/2 positive cases increased from 33% to 51% from the γH2AX negative to the γH2AX positive group (p=0.04) (Fisher’s 
exact test). (G) Bar graphs showing a significantly increased incidence of γH2AX, pCDC25c, and pCHK1/2 positive cases in the c-MYC 
positive subgroup, compared to the c-MYC negative subgroup. The 3 cases with missing c-MYC values were excluded from this analysis.
(Continued )
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and constitutive expression of γH2AX, evaluated by 
Western blot analysis.
The HL cell line KMH2 showed low or absent basal 
levels of activation of the DDR pathway, which did not 
translate in increased γH2AX expression (Figure 2A). In 
line with the results of the immunohistochemical study, we 
found a significant correlation between c-MYC levels and 
pCHK1 ser 345 levels (Figure 2B). Finally, primary cells 
from 2 out of 3 aggressive B-cell lymphoma patients (2 
DLBCL, 1 BL) showed constitutive γH2AX expression. 
We did not find γH2AX overexpression in indolent 
B-cell lymphoma primary cells and normal bone marrow 
mononucleated cells (Figure 2C).
To evaluate the therapeutic potential of CHK 
inhibition, we incubated B-cell lymphoma cell lines with 
increasing concentrations of PF-0477736 from 5 nM 
to 10 μM. Cell viability was assessed by WST-1 assay 
(Roche). PF-0477736 is a selective ATP competitive CHK 
inhibitor with IC50 of 2 and 47 nM respectively for CHK1 
and CHK2, which was demonstrated to have activity in 
preclinical models of solid tumours in combination with 
DNA damaging agents [22, 23]. PF-0477736 induced cell 
death in a time and dose dependent manner, with a maximal 
effect after 48 hours. The most sensitive cell line was 
BJAB, with an IC50 of 48 nM and 9nM at 24 and 48 hours 
(hrs) respectively (Figure 2D, 2E). KM-H2 cells were 
resistant. All the other DLBCL cell lines were sensitive 
to nanomolar concentrations of PF-0477736, with IC50s 
ranging from 160 to 230 nM (Figure 2D, 2E). The resistant 
KM-H2 cells did not display any constitutive expression of 
γH2AX and pCHK2, and only weak pCHK1 and c-MYC 
expression (Figure 2A). These results were confirmed also 
by using a different inhibitor of CHK kinases, AZD-7762 
[24], which also displayed submicromolar IC50 values 
at 48 hours (Fig S1) in DLBCL and BL cell lines. Taken 
together these observations indicate a high efficacy of 
CHK inhibitors against DLBCL cell lines characterized 
by constitutive activation of the DDR pathway.
Since some reports link the sensitivity to CHK 
inhibition to the dysfunction of the p53 axis in different 
tumor models [22, 24], we profiled our cell lines by 
conventional Sanger sequencing for the presence of TP53 
mutations and CDKN2A deletions, (known recurrent 
genomic alterations in DLBCL which result in p53 axis 
and G1/S checkpoint dysfunction). Alterations resulting 
in G1/S checkpoint dysfunction were found in all the 
DLBCL cell lines and in the BL cell line RAMOS and 
only the resistant KM-H2 cells were TP53 wild type 
with no alteration of CDKN2A (Figure 2E) (Table S3). 
Notably, in line with previous reports [22, 24], co-
treatment with the CHK inhibitor PF-0477736 enhanced 
the efficacy of doxorubicin in the TP53 mutant DLBCL 
cell lines (Figure S2A).
In order to establish the relevance of p53 status in 
the cytotoxic activity of PF-0477736, we induced stable 
transfection of the TP53/ wild-type KM-H2 cells with the 
dominant negative mutant p53dd. Interestingly we failed 
to induce sensitivity to PF-0477736 single agent or in 
combination with doxorubicin after p53dd transfection 
(Figure S2 B–D). These results indicate that at least in 
this cellular context disruption of p53 function is not 
sufficient to induce sensitivity to CHK inhibition or to 
combinations with doxorubicin, and that probably other 
mechanisms cooperate in determining the sensitivity to 
CHK inhibition and dependence on the G2/M checkpoint 
in these cells.
To further investigate the mechanisms of action 
of PF-0477736 we determined the effect on apoptosis 
by using Annexin V/Propidium Iodide staining. In line 
with WST-1 assay results, low nanomolar concentrations 
of PF-0477736 induced cell death by apoptosis after 24 
hours of incubation in the sensitive BJAB cells, but not 
in the resistant KM-H2 cells (Figure 3A, 3B). Consistent 
with the induction of apoptosis PARP cleavage was 
detected by western blot after 24 hours in BJAB cells 
(Figure 3C).
Factor γH2AX- (N=52) γH2AX+ (N=47) Missing p-value (Fisher’s 
exact test)
pCHK1/2 0 0.04
< 30% 35 (67%) 23 (49%)
≥ 30% 17 (33%) 24 (51%)
pCDC25c 0 < 0.001
< 30% 43 (83%) 16 (34%)
≥ 30% 9 (17%) 31 (66%)
P value was calculated with the Fisher’s exact test
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Figure 2: The CHK inhibitor PF-0477736 shows potent antiproliferative activity in aggressive B-cell lymphoma 
cells. (A) Western immunoblotting showing the activation status of the DDR pathway and the expression of the DNA damage marker 
γH2AX in DLBCL, BL, and HL cells. The GCB-derived DLBCL cell lines BJAB, SUDHL-4, SUDHL-6, the ABC-derived cell lines  
HBL-1, U-2932, TMD8, the BL cell line RAMOS and the HL cell line KM-H2 were harvested during the exponential growth phase, and 
assessed for the expression levels of pCHK1 ser345, CHK1, pCHK2 thr 68, CHK2, γH2AX, and c-MYC. (B) Graph showing correlation 
between c-MYC and pCHK1 ser 345 expression levels in our panel of B-cell lymphoma cell lines, as evaluated by densitometry analysis 
using the ImageJ software (National Institutes of Health, Bethesda, MD). Pixel density is expressed in arbitrary units. The p value of 
the correlation was calculated with Spearman and Pearson’s tests. (C) Western blot assay showing the expression of the DNA damage 
marker γH2AX in primary aggressive B-cell lymphoma cells, indolent B-cell lymphoma cells, and normal bone marrow progenitors. BL 
(Burkitt lymphoma), DLBCL (Diffuse large B-cell lymphoma), CLL (Chronic Lymphocytic Leukemia), HCL (Hairy Cell Leukemia), 
NBM (Normal bone marrow mononucleated cells). The BJAB cell line was used as a positive control. (D) WST-1 assay of DLBCL, BL, 
HL cell lines treated with increasing concentrations of the CHK 1/2 kinase inhibitor PF-0477736 for 24 and 48 hours. Each value is the 
mean of three independent experiments performed in triplicate. Error bars represent standard error of the mean (s.e.m). (E) IC50 values after 
48 hours of incubation with PF-0477736. After 48 hours of incubation with PF-0477736 the DLBCL GCB-derived BJAB cells were the most 
sensitive with an IC50 value of 9 nM. All other DLBCL cell lines were sensitive to nanomolar concentrations of PF-0477736, displaying IC50 
values between 160 and 230 nM. Only the HL derived KM-H2 cells were resistant to treatment with an IC50 value of 7 μM at 48 hours. The 
black and white squares represent the presence or absence of TP53 mutations and/or CDKN2A deletions in DLBCL cells.
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Figure 3: PF-0477736 induces cell death by apoptosis in DLBCL cell lines. (A) Representative experiment demonstrating 
the effect of different doses of PF-0477736 (25 or 50nM for 24 h in BJAB cells, 250 and 500 nM for 24 h in KM-H2 cells) on apoptosis 
as determined by annexin V-propidium iodide (PI) binding assay. The percentage of dead cells is shown in the upper right quadrant. 
(B) Summary of the results of dual annexin V and propidium iodide (PI) staining. Each value is the mean of three independent experiments 
performed in triplicate. Error bars represent s.e.m. *P < 0.05; **P < 0.005; NS (not significant). (C) Immunoblotting showing cleavage of 
poly (adenosine diphosphate ribose) polymerase (PARP) in BJAB cells after 24 hours of incubation with increasing doses (50, 250, 500 
nM) of PF-0477736, with respect to control (C) (DMSO). Consistent the results of annexin V and propidium iodide staining no PARP 
cleavage was observed in the resistant KM-H2 cells following treatment. (D) Summary of the results of dual annexin V – (PI) staining for 
different DLBCL cell lines. Each value is the mean of three independent experiments performed in triplicate. Error bars represent s.e.m. 
*P < 0.05; **P < 0.005.
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Nanomolar concentrations of PF-0477736 induced 
apoptotic cell death also in the other DLBCL cell lines 
tested at 48 hours (Figure 3D).
PF-0477736 inhibits CDC25c phosphorylation 
and determines rapid DNA damage 
accumulation in DLBCL cell lines
Following DNA damage, the activation of CHK1 
and CHK2 results in the inhibitory phosphorylation of 
the CDC25c phosphatase, which determines inhibition of 
mitotic entry, allowing DNA repair [13]. Therefore, the 
impairment of the G2/M checkpoint mediated by CHK 
inhibition should determine an uncontrolled DNA damage 
accumulation leading to replication fork collapse followed 
by cell death.
To verify this hypothesis we first incubated the 
sensitive BJAB cells and the resistant KM-H2 cells with 
increasing concentrations of PF-0477736 and assessed 
effects on CDC25c and γH2AX phosphorylation. 
PF-0477736 potently inhibited the phosphorylation 
of CDC25c at ser 216 in the sensitive BJAB cells. As 
CDC25c de-phosphorylation triggers its proteasome 
dependent degradation, in line with recent findings [25] 
we also observed a decrease in total CDC25c levels 
following treatment. Moreover we observed a rapid and 
marked dose dependent increase of γH2AX consistent 
with accumulation of DNA damage (Figure 4 A, 4B). On 
the contrary, in KM-H2 cells we did not observe increased 
γH2AX levels following PF-0477736 treatment (western 
blot and immunofluorescence), and consistent with the 
low activation status of the DDR pathway, these cells 
did not show any constitutive CDC25c phosphorylation 
(Figure 4A). Taken together, these findings show that 
inhibition of the CHK kinases effectively increases the 
amount of DNA damage in DLBCL cells without the 
presence of exogenous genotoxic sources. In line with 
these results, incubation with PF-0477736 for 24 hrs 
Figure 4: PF-0477736 inhibits CDC25c phosphorylation and determines DNA damage accumulation in DLBCL 
cells. (A) Western blot assay of BJAB and KM-H2 cells treated with increasing concentrations of PF-0477736 (50, 250, 500 nM) for 24 
hours, showing inhibition of the donwstream target pCDC25c ser 216 and contemporary upregulation of the DNA damage marker γH2AX 
in the sensitive BJAB cells. On the contrary we could not detect any γH2AX induction in the resistant KM-H2 cells. Of note KM-H2 cells 
did not show any basal CDC25c phosphorylation, consistent with the low level of DDR activation shown in Figure 1. C (control, DMSO).
(B) Early effects of PF-0477736 on γH2AX phosphorylation levels. Immunofluorescence of BIAB and KM-H2 cells indicating increased 
γH2AX levels as soon as after 3 hours of incubation with PF-0477736 (PF) 250 nM in the BJAB cells. Consistent with Fig. 5A, the resistant 
KM-H2 cells did not show significant γH2AX upregulation following treatment. (C) Effects of PF-0477736 on the upstream components of 
the DDR pathway. BJAB and KM-H2 cells were incubated with increasing concentrations of PF-0477736 (50, 250, 500 nM) for 24 hours 
and effects on ATM, CHK1 and CHK2 phosphorylation assessed by western blot. Consistent with DNA damage induction, PF-0477736 
triggered a futile feedback loop in the sensitive BJAB cells, with increased ATM activation resulting in hyperphosphorylation of CHK1 and 
CHK2. C (control, DMSO).
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triggered a futile feedback loop resulting in increased 
phosphorylation of ATM, and both its targets CHK1 
and CHK2, as previously reported with different CHK 
inhibitors [26] (Figure 4C). The position and function 
of different components of the DDR pathway is briefly 
elucidated in Figure 4D.
A similar mechanism resulting in DNA damage 
accumulation and hyper-phosphorylation of CHK1, was 
observed in all the DLBCL cell lines tested (Figure 4E).
PF-0477736 shows high single agent activity and 
promotes DNA damage in primary aggressive 
B-cell lymphoma cells
To investigate the activity of PF-0477736 in primary 
lymphoma cells and to evaluate its toxicity on bone 
marrow mononucleated cells we incubated a panel of 
primary cells from aggressive B-cell lymphoma patients 
(n = 5) [2 BL, 2 DLBCL, 1 mantle cell lymphoma blastoid 
variant (MCL)], indolent B-cell lymphoma patients (n = 5) 
(3 CLL, 1 MZL, 1 hairy cell leukemia) and normal bone 
marrow progenitors (n = 7), with PF-0477736 at the fixed 
dose of 500 nM for 24 hours.
Consistently with our previous findings, 
aggressive B-cell lymphoma primary cells were 
sensitive to PF-0477736, whereas primary indolent 
B-cell lymphoma cells were only slightly sensitive and 
normal bone marrow progenitors were resistant (Figure 
5A). Of note, in DLBCL primary cells PF-0477736 
induced DNA damage accumulation with increase 
of γH2AX and pCHK1, as already demonstrated in 
DLBCL cell lines (Figure 5B). Characteristics of 
patients whose cells were used for ex-vivo experiments 
are shown in Figure 5C.
PF-0477736 displayed activity both in TP53 wild 
type and mutant primary cells, although the highest 
activity was observed in a TP53 mutant Burkitt lymphoma 
sample (BL#2) (Figure 5B) (Table S3).
These data strongly suggest that PF-0477736 
may exert a selective cytotoxic activity on aggressive 
lymphoma cells, without inducing specific changes in 
normal bone marrow mononucleated cells, at least in short 
term culture.
DISCUSSION
In this study we addressed the value of targeting 
the DDR pathway in aggressive B-cell lymphomas, 
focusing the attention on DLBCL. First we demonstrated 
that DLBCL is a neoplasm characterized by high 
inherent genomic instability and that the DDR pathway 
is aberrantly active in DLBCL cell lines, primary cells, 
and DLBCL tissue samples. In our patient cohort about 
half of all patients showed high levels of the DNA damage 
marker γH2AX and activation of the DDR components at 
the moment of initial diagnosis. We observed a significant 
correlation between γH2AX expression levels, constitutive 
DDR activation and c-MYC overexpression, suggesting 
an intimate relationship between MYC-induced oncogenic 
stress, genomic instability and DDR activation in DLBCL 
Figure 4: (Continued) (D) Model of activation of the DDR pathway and G2/M checkpoint after DNA damage. After DNA damage, the 
histone H2AX is promptly recruited at the DNA damage foci and phosphorylated. The ATR and ATM kinases phosphorylate CHK1 and 
CHK2 which in turn phosphorylate the downstream target CDC25c phosphatase. This inhibitory phosphorylation results in cell cycle 
arrest, allowing DNA repair. The CHK2 kinase participates also in the G1/S checkpoint, by stabilizing p53 after DNA damage. (E) The 
GCB-derived SUDHL-4 cells and the ABC-derived U-2932 and TMD8 cells were incubated with PF-0477736 250 nM for 24 hours. BJAB 
cells were used as a control. Consistent with the data shown in Fig. 5A and 5B, an induction of γH2AX and pCHK1 ser 345 was observed 
in all DLBCL cell lines. At the same time point, PARP cleavage consistent with apoptosis induction was detected in all DLBCL cell lines.
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(Fig. 1E). Moreover, patients showing high γH2AX 
expression had a statistically significant lower 5-year OS 
compared to patients with low levels of γH2AX following 
conventional chemoimmunotherapy (Fig. 1C, 1D). These 
findings indicate that constitutive DDR activation could 
determine resistance to therapy with DNA damaging 
agents and that the DDR could be an important therapeutic 
target in DLBCL.
We demonstrated in in vitro and ex-vivo models 
that targeting the DDR pathway by inhibition of CHK 
kinases could be an effective treatment strategy in the 
subset of DLBCL with constitutive activation of DDR. 
Treatment with the CHK1/2 inhibitor PF-0477736 as 
single agent induced cell death by apoptosis at nanomolar 
concentrations in DDR positive DLBCL cell lines and 
markedly inhibited cell viability in primary DLBCL 
and BL cells. The antiproliferative affects observed 
with PF-0477736 in DLBCL cells were recapitulated by 
using a different inhibitor of CHK kinases (AZD7762), 
indicating a specific class effect of these compounds in 
DLBCL. Inhibition of CHK kinases effectively resulted in 
inhibition of the phosphorylation of the downstream target 
CDC25c, and increased the phosphorylation of the DNA 
damage marker γH2AX both in DLBCL cell lines and 
primary cells. Interestingly the increased amount of DNA 
damage determined by CHK inhibition triggered a futile 
feed-back loop characterized by enhanced ATM activation 
and hyperphosphorylation of CHK1 and CHK2, which 
could be used as a biomarker of activity in future clinical 
trials. Notably we did not observe any in vitro cytotoxicity 
in normal bone marrow progenitors. Our results also 
indicate that the sensitivity to CHK inhibition of the DDR 
negative TP53-wild type KM-H2 cells was unaffected 
by transfection with the dominant negative p53 mutant 
p53DD, suggesting that the p53 status is not a primary 
determinant of sensitivity to DDR inhibition, and that the 
presence constitutive DDR activation likely plays a major 
role. On the other hand it is noteworthy that single agent 
PF-0477736 showed activity in TP53 mutant aggressive 
B-cell lymphoma cell lines and primary cells, and that 
combined treatment with PF-0477736 was able to revert 
resistance to doxorubicin in TP53 mutant cells (Figure S2). 
These observations suggest that inhibition of checkpoint 
kinases could be an effective treatment strategy for TP53 
mutant chemoresistant lymphomas with aberrantly active 
DDR pathway. These data are in line with previously 
published work showing single agent activity of CHK 
inhibitors in MYC driven lymphoma mouse models which 
recapitulate human Burkitt lymphoma [16], suggesting 
that Burkitt lymphoma and DLBCL share dysregulation 
of the DDR as a common pathogenetic feature. The role 
of DDR pathway and its upstream components [such as 
DNA dependent protein kinase (DNA-PK) and ATM] as 
therapeutic targets in MYC driven lymphomas has been 
confirmed in a recent report by Johnstone and coworkers 
on the efficacy of combined inhibition of ATM, DNA-PK 
and mammalian target of rapamycin (mTOR) in Eμ-MYC 
lymphoma models [27]. Intriguingly previous work from 
Blagosklonny and coworkers showed that enhanced DDR 
signaling was associated with mTOR over-activation 
during senescence coupled with hyper-mitogenic drive, 
and that inhibition of mTOR signaling by rapamycin 
attenuated DDR activation related to senescence [28, 29]; 
since oncogene-induced replicative stress may lead to 
Figure 5: Effects of PF-0477736 in primary lymphoma cells and bone marrow mononucleated cells. (A) Normal bone 
marrow mononucleated cells harvested from 7 patients with no signs of bone marrow involvement, at the moment of initial diagnosis, 5 
primary indolent B-cell lymphoma samples, and 5 primary aggressive B-cell lymphoma samples were incubated with PF-0477736 500 nM 
for 24 hours, and cell viability evaluated by trypan-blue staining. The viability of each primary sample was normalized to its own untreated 
control. Error bars represent s.e.m. BL (Burkitt lymphoma), DLBCL (Diffuse large B-cell lymphoma), CLL (Chronic Lymphocytic 
Leukemia), HCL (Hairy Cell Leukemia), NBM (Normal bone marrow mononucleated cells), MZL (Marginal zone lymphoma), MCL 
(Mantle cell lymphoma).
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cellular senescence and DDR activation [30], and given 
that active mTOR signaling and c-MYC expression 
have been demonstrated to be significantly associated in 
DLBCL [31], it is tempting to think that mTOR and MYC 
may cooperate in inducing aberrant DDR activation, and 
that dual targeting of DDR and mTOR could be a valuable 
strategy in DLBCL.
Moreover it has been recently reported that inherent 
DNA damage is a common trait shared by a variety of 
haematological cancer cell lines of both myeloid and 
lymphoid origin [32]. These findings, together with our 
observations, suggest that genomic instability, inherent 
DNA damage and alterations in DNA repair pathways may 
represent an Achilles heel by which highly genetically 
unstable aggressive lymphoid neoplasms may be targeted 
therapeutically.
Collectively, our observations depict a model of 
synthetic lethality in which cells with high oncogene 
induced genomic instability carry higher levels of 
constitutive DDR activation in order to cope with 
oncogene-induced replicative stress, and are thus sensitive 
to CHK inhibition, according to the oncogene-induced 
DNA damage model for cancer development proposed by 
Halazonetis and coworkers [11] (Figure 6). In conclusion, 
Figure 5: (Continued) (B) Western blot assay showing on treatment modifications of γH2AX and pCHK1 ser 345 in primary cells. 
Similarly to what we observed in cell lines, treatment with PF-0477736 determined DNA damage accumulation with increased γH2AX 
and pCHK1 ser 345 levels in DLBCL primary cells, whereas no changes were observed in primary B-CLL cells and normal bone 
marrow mononucleated cells (NBM). (C) Table showing characteristics of patients whose primary cells were harvested and used for the 
experiments above.
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our data demonstrate that inherent genomic instability and 
DDR pathway constitutive activation are frequent features 
in DLBCL, and are associated with a poor prognosis. The 
high efficacy of CHK inhibitors in DLBCL cell lines and 
primary cells characterised by aberrantly active DDR 
pathway, strongly suggest that the constitutive activation 
of this pathway may represent a novel therapeutic target, 
providing a rationale for further clinical evaluation of this 
therapeutic strategy in DLBCL.
METHODS
Immunohistochemistry and primary tissues
Ten tissue microarrays (TMAs) were obtained from 
formalin-fixed paraffin-embedded samples collected 
at diagnosis from 3 reactive lymph nodes from 27 
Chronic lymphocytic lymphoma/Small Lymphocytic 
lymphoma (CLL/SLL), 18 Splenic marginal zone 
lymphoma (SMZL), 22 Burkitt lymphoma (BL) and 
44 classical Hodgkin lymphoma (CHL) cases and from 
99 consecutive patients affected by DLBCL; the latter 
were classified in GCB (46 cases) and Non-GCB (53 
cases) according to Hans algorithm [33]. All DLBCL 
cases were treated at our Institution with R-CHOP/
CHOP-like regimens. All cases were retrieved from the 
archives of the Haematopathology Unit, Department 
of Experimental, Diagnostic and Specialty Medicine - 
DIMES, University of Bologna and were diagnosed 
from 2002 to 2011. The protocol was approved by the 
institutional review board of the University of Bologna. 
Informed consent was obtained from all patients. TMAs 
Figure 6: Proposed model of oncogene induced genomic instability in DLBCL. Constitutive expression of oncogenes such as 
MYC increases replicative stress and determines G1/S checkpoint activation, which in normal cells leads to apoptotic cell death. Aggressive 
B-cell lymphoma cells tolerate increased amounts of genomic instability by constitutive activation of the G2/M checkpoint/DDR pathway 
(ATM-ATR-CHK1-CHK2-CDC25c axis). Inhibition of the DDR pathway by CHK inhibitors (CHKi) acts as a synthetic lethal mechanism, 
leading to “uncontrolled” genomic instability and cell death.
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were constructed as previously reported [34]. TMAs 
sections were investigated by antibodies raised against 
fixation resistant epitopes of CHK1, p-CHK1 serine 
(ser) 345, CHK2, p-CHK2 threonine (thr) 68, CDC25, 
p-CDC25 ser 216, p-H2AX ser 319, c-MYC, BCL2, Ki67 
and P53 proteins; the antibody reactivity and sources 
as well as the antigen retrieval protocols, dilutions and 
revelation systems are detailed in supplementary Table 
S4. The cutoff for positivity was set at 30% of cells 
expressing the protein of interest, unless otherwise 
specified [34]. For Bcl-2 and c-MYC we applied a cut-
off of 70% and 40%, whereas for p53 staining a cut-off 
of 50% was applied, according to the recent literature [9, 
35]. Immunohistochemical preparations were visualized 
and images were captured using Olympus Dot-slide 
microscope digital system equipped with the VS110 
image analysis software.
Cell lines and primary cells
The human DLBCL-derived cell lines SUDHL-4, 
SUDHL-6, the HL cell line KM-H2 and the BL cell line 
RAMOS were obtained from the German Collection 
of Microorganisms and Cell Cultures, Department 
of Human and Animal Cell Cultures (Braunschweig, 
Germany). The DLBCL derived cell lines (HBL-1, 
U2932, TMD8, BJAB) were kindly provided by Dr. R.E. 
Davis (Houston, Tx). Cell lines were cultured in RPMI 
1640 medium supplemented with 10% heat-inactivated 
fetal bovine serum (GIBCO BRL, Gaithersburg, MD), 
1% L-glutamine, and penicillin-streptomycin in a humid 
environment of 5% CO2 at 37°C. The phenotypes and 
genotypes of these cell lines have been previously 
described [36, 37].
Primary cells from patients were obtained from 
bone marrow samples, peripheral blood of leukemic 
phase patients with more than 90% of circulating blasts, 
neoplastic abdominal and pleural effusions. Normal bone 
marrow progenitors were harvested from bone marrow 
aspirations performed in lymphoma patients undergoing 
initial staging procedures, which then resulted negative for 
lymphoma infiltration.
In vitro proliferation assay
Cells were seeded in 96-well plates at 50,000 
cell/100 μl/well with increasing concentrations of drug 
(0.005–10 μM) for 24 and 48 hours. Cell viability was 
assessed by adding WST-1 reagent (Roche Applied 
Science, Basel, Switzerland) to the culture medium at 
1:10 dilution, according to manufacturer’s instructions. 
Viability of primary cells was assessed by using the trypan 
blue staining, in triplicate experiments.
Statistical analyses
Survival analyses were performed using the Kaplan-
Meier method and differences between groups calculated 
by using the log-rank test [38]. Multivariate analyses 
were performed by using the Cox regression model. 
Procedures to determine the effects of certain conditions 
on cell proliferation and apoptosis, were performed in 
3 independent experiments. The 2-tailed Student t test 
was used to estimate the statistical significance of the 
differences between results from the 3 experiments. The 
Fisher’s exact test was used to estimate differences in 
proportions between groups. The Pearson and Spearman’s 
tests were used to establish correlations between different 
variables. Quantification of protein-band intensities by 
densitometric analysis was performed using NIH ImageJ 
software (National Institutes of Health, Bethesda, MD). 
Hierarchical clustering of immunohistochemical results, 
displayed in dendrogram in Figure 1A, was generated as 
reported in supplementary material. The SPSS and PRISM 
softwares were used for the statistical analyses. Detailed 
methods are available in supplemental data.
Western blotting, immunofluorescence and flow 
cytometry
Preparation of cellular protein lysates, protein 
quantitation, western immunoblotting and flow cytometry 
were performed as previously described [39, 40]. A total 
of 30 μg of protein was denatured in Laemmli buffer at 
95°C and separated by SDS-PAGE. Proteins were then 
electrotransferred onto nitrocellulose membranes and 
submitted to immunodetection with the relevant antibody. 
Membrane-bound secondary antibodies (HRP-conjugated 
goat anti-rabbit or anti-mouse, BioRad) were detected 
using SuperSignal West Dura Extended Duration Substrate 
(Pierce Chemical Co., Rockford, IL).
Immunofluorescence
Cells were seeded on poly-L-lysine coated glass 
coverslips and incubated overnight at 4°C. Samples 
were incubated for 1 hour in PBS plus 1% Bovine Serum 
Albumin (Sigma- Aldrich) to block unspecific binding 
before incubating with the primary antibody (Cell 
Signaling) diluted 1:400 in PBS 1% BSA overnight at 
4°C. The samples were rinsed in PBS and then incubated 
with secondary antibody Alexa fluor 568 goat anti-rabbit 
IgG (Life Technologies) for 40 min at 37°C in darkness. 
Mounting and nuclei counterstaining were performed 
using the “pro long antifade reagent with DAPI” 
(Molecular Probes, Invitrogen) and observed under a 
fluorescence microscope.
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Flow cytometry
Apoptosis was determined by using the Annexin V–
FITC apoptosis detection kit (BD Pharmingen, San Diego, 
CA) according to the manufacturer’s instructions. Data 
were collected on a FACS Canto II flow cytometer (BD 
Biosciences, San Jose, CA) using FlowJo software (Tree 
Star, Ashland, OR).
Antibodies for western blotting, 
immunofluorescence and immunohistochemistry
For western blotting, antibodies to the following 
were purchased from Cell Signaling Technology: 
p-CHK1 ser 317, p-CHK1 ser 345, CHK1, pCHK2 thr 
68, p-H2AX ser 139 (also used for immunofluorescence 
and immunohistochemistry), p-CDC25c ser 216, CDC25c, 
p-ATM ser 1981, ATM. C-MYC antibody was purchased 
from Abcam. For immunohistochemical studies, antibodies 
were obtained from Novus biologicals (CHK1, pCHK1ser 
345, pCDC25 ser 216), Cell Signaling (Danvers, 
MA) (pCHK2 thr 68, p- H2AX ser 319), Epitomics 
(Burlingame, CA) (CHK2, CDC25, c-MYC), Menarini 
(Florence, Italy) (P53).
Reagents and proliferation assays
The CHK1/2 inhibitors PF-0477736 and AZD-
7762 were purchased from Selleckchem (Houston, TX). 
Doxorubicin was purchased from Sigma Chemicals 
(Milan, Italy).
Production of KM-H2 -derived cells with stably 
inactivated p53
KM-H2 cells stably expressing p53DD, a truncated, 
dominant-negative form of murine p53 [41]and the related 
empty vector-transduced control cells (pBABE), were 
obtained as described by Morgenstern JP and Land H [42]. 
These cell lines were maintained in RPMI supplemented 
with 10% FBS and selected with puromycin antibiotic 
(Sigma-Aldrich, Milan, Italy).
Sanger sequencing of TP53 and CDKN2A/B genes
Detailed information on primer sequences, and 
Sanger sequencing of CDKN2A/B genes are available in 
supplemental data.
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